Roche Backs Off Mircera Suit In India
Roche has dropped its suit against Intas Pharmaceuticals Ltd. over the alleged infringement of its patents pertaining to Mircera (methoxy polyethylene glycol-epoetin beta), after the Indian firm apparently established that its product is "different". Both sides, though, seemed to keep the matter alive, suggesting that they would seek appropriate remedies in the event of fresh "cause of action".
You may also be interested in...
Cut-price versions of Roche's anticancer, Avastin (bevacizumab), may well be on their way to the Indian market after a key local expert panel recently recommended the biosimilars for marketing. And "improvements" to facilitate off-label use of the product also appear to be on the agenda of some biosimilar players.
The hotly contested case concerning biosimilar versions of Roche's Herceptin (trastuzumab) witnessed a seesaw shift after a division bench of the Delhi High Court held that the status prevailing prior to a stinging April 25 order against Biocon Ltd. and Mylan NV will continue to operate.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.